NVNO

NVNO

USD

enVVeno Medical Corporation Common Stock

$2.735-0.031 (-1.121%)

Prix en Temps Réel

Healthcare
Dispositifs médicaux
États-Unis

Graphique des Prix

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$2.766

Haut

$2.766

Bas

$2.660

Volume

0.00M

Fondamentaux de l'Entreprise

Capitalisation Boursière

48.0M

Industrie

Dispositifs médicaux

Pays

United States

Statistiques de Trading

Volume Moyen

0.09M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $2.028Actuel $2.735Haut $6.48

Actualités Connexes

AccessWire

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies hereFRENCHTOWN, NJ / ACCESS Newswire / February 19, 2025 / JTC Team , a fully integrated corporate communications and investor

Voir plus
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand
AccessWire

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life indicators.PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the

Voir plus
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
AccessWire

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.78% of subjects maintained a clinically meaningful

Voir plus
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.